EGFR and head and neck squamous cell carcinoma: Here we assessed whether the combination of two therapeutic monoclonal antibodies, cetuximab, and IMC-A12 that specifically target EGFR and IGF-1R, respectively, would enhance HNSCC tumor response to radiation.